扶正抑瘤方联合mFOLFOX6治疗对结肠癌患者肠道菌群的影响  

Effect of Fuzheng Yiliu Fang combined with mFOLFOX6 on intestinal flora in patients with colon cancer

作　　者：胡嘉芮 渠少博 何晓华[1] 刘戴维 王永霞 李占林[1] HU Jiarui;QU Shaobo;HE Xiaohua;LIU Daiwei;WANG Yongxia;LI Zhanlin(Department of Traditional Chinese Medicine,the First Affiliated Hospital of Hebei North University,Zhangjiakou 075061,Hebei Province,China)

机构地区：[1]河北北方学院附属第一医院中医科,河北张家口075061

出　　处：《世界临床药物》2024年第4期385-390,共6页World Clinical Drug

基　　金：河北省中医药管理局科研计划项目(2022423)。

摘　　要：目的探讨扶正抑瘤方联合mFOLFOX6治疗对结肠癌患者临床受益率及肠道菌群的影响。方法选择2021年2月至2023年5月本院收治的106例晚期结肠癌患者,并按随机数字表法分为化疗组(mFOLFOX6化疗)和联合组(在化疗组基础上联合扶正抑瘤方治疗),每组53例。比较两组临床受益率、肠道菌群、免疫指标及不良反应发生率。结果联合组临床受益率(84.31%)高于化疗组(64.00%,P<0.05);治疗后,联合组双歧杆菌、乳酸杆菌数量高于治疗前,且高于化疗组(P<0.05),大肠埃希菌低于治疗前,且高于化疗组(P<0.05);治疗后,联合组CD4^(+)、CD4^(+)/CD8^(+)水平高于化疗组,且CD8^(+)低于化疗组(P<0.05);联合组胃肠道反应(29.41%)、骨髓抑制发生率(13.73%)低于化疗组(66.00%,32.00%,P<0.05)。结论对晚期结肠癌患者应用扶正抑瘤方联合mFOLFOX6治疗,可有效调节肠道菌群,明显减轻化疗对免疫功能的影响,显著降低胃肠道反应、骨髓抑制等不良反应,并有助于提高临床受益率。Objective To investigate the effect of Fuzheng Yiliu Fang combined with mFOLFOX6 chemotherapy on the clinical benefit rate and intestinal flora of patients with colon cancer.Methods A total of 106 patients with advanced colon cancer admitted to our hospital from February 2021 to May 2023 were selected and divided into chemotherapy group(mFOLFOX6 chemotherapy)and combination group(combined with Fuzheng Yiliu Fang on the basis of chemotherapy group)according to random number table method,with 53 cases in each group.The efficacy,intestinal flora,immune indexes and incidence of adverse reactions were compared between the two groups.Results The clinical benefit rate of combination group(84.31%)was higher than that of chemotherapy group(64.00%,P<0.05).After treatment,the number of Bifidobacterium and Lactobacillus in combination group was higher than before treatment and higher than that in chemotherapy group(P<0.05),and the number of Escherichia coli was lower than before treatment and higher than that in chemotherapy group(P<0.05).After treatment,the levels of CD4^(+)and CD4^(+)/CD8^(+)in combination group were higher than those in chemotherapy group,and CD8^(+)was lower than that in chemotherapy group(P<0.05).The incidence of gastrointestinal reaction(29.41%)and myelosuppression(13.73%)in combination group were lower than those in chemotherapy group(66.00%,32.00%,P<0.05).Conclusion Fuzheng Yiliu Fang combined with mFOLFOX6 can effectively regulate intestinal flora,significantly reduce the impact of chemotherapy on immune function,significantly reduce gastrointestinal reactions,bone marrow suppression and other adverse reactions of chemotherapy in the treatment of advanced colon cancer patients,and help to improve the clinical benefit rate.

关 键 词：扶正抑瘤方 mFOLFOX6化疗 结肠癌 临床受益率 肠道菌群 

分 类 号：R735.3[医药卫生—肿瘤]